| Chen, likun |
NCT05768490: Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases |
|
|
| Recruiting | 3 | 232 | RoW | brain radiotherapy, Almonertinib | Sun Yat-sen University | Brain Metastases, Radiotherapy, EGFR Activating Mutation | 12/28 | 12/29 | | |
SUPER BRAIN, NCT05807893: Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases |
|
|
| Completed | 2/3 | 40 | RoW | Serplulimab combined with bevacizumab and first-line chemotherapy | Sun Yat-sen University | Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases | 03/24 | 05/24 | | |
GASTO 1063, NCT04978753: the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Anlotinib, almonertinib | Li-kun Chen | Non-small Cell Lung Cancer, Brain Metastases | 05/22 | 12/23 | | |
NCT04213170: Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | sintilimab, bevacizumab | Sun Yat-sen University | Brain Metastases, Non Small Cell Lung Cancer, Sintilimab, Bevacizumab | 12/22 | 12/22 | | |
NCT05207904: Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases |
|
|
| Recruiting | 2 | 41 | RoW | Tislelizumab, paclitaxel, Carboplatin | Sun Yat-sen University | Non-Small Cell Squamous Lung Cancer, Brain Metastases | 12/22 | 06/23 | | |
NCT04094909: Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 186 | RoW | Rh-endostatin, Pembrolizumab, carboplatin, cisplatin, pemetrexed, [nab]-paclitaxel | Guangzhou Institute of Respiratory Disease | Staging IV NSCLC | 12/22 | 03/23 | | |
NCT06684873: A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) |
|
|
| Not yet recruiting | 2 | 55 | RoW | AK112 Injection | Sun Yat-sen University | NSCLC, Brain Metastasases | 12/27 | 12/27 | | |
| Zhou, Chengzhi |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06607796: Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy |
|
|
| Recruiting | 3 | 180 | RoW | Toluenesulfonamide (PTS) Intratumoral Injection | Zhou Chengzhi | Lung Cancer | 12/26 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT04312204: Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab combined with Gemcitabine and Carboplatin | Zhou Chengzhi | Primary Pulmonary Lymphoepithelioma-like Carcinoma, Lung Cancer | 08/21 | 08/22 | | |
NCT04316351: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Recruiting | 2 | 60 | RoW | Toripalimab + Pemetrexed + Anlotinib, JS001 | Guangzhou Institute of Respiratory Disease, Shanghai Junshi Bioscience Co., Ltd. | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | 04/22 | 04/22 | | |
NCT04094909: Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 186 | RoW | Rh-endostatin, Pembrolizumab, carboplatin, cisplatin, pemetrexed, [nab]-paclitaxel | Guangzhou Institute of Respiratory Disease | Staging IV NSCLC | 12/22 | 03/23 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
| Not yet recruiting | 2 | 30 | NA | Serplulimab, Lurbinectedin, PM01183, Carboplatin, Etoposide | Guangzhou Institute of Respiratory Disease | Extensive-Stage Small Cell Lung Cancer | 06/25 | 12/25 | | |
NCT06739928: Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC |
|
|
| Recruiting | 2 | 120 | RoW | Irinotecan liposome (II) combined with adebrelimab and carboplatin, etoposide combined with adebrelimab and carboplatin | Guangzhou Institute of Respiratory Disease | Small Cell Lung Cancer Extensive Stage | 06/26 | 12/27 | | |
| Recruiting | 1/2 | 30 | RoW | Blood-stage infection of P. vivax | State Key Laboratory of Respiratory Disease, CAS Lamvac Biotech Co., Ltd. | Lung Cancer, Nonsmall Cell | 07/20 | 12/23 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | TQ-B3525 Tablets, Osimertinib Mesylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nonsmall-cell Lung Cancer | 04/24 | 06/24 | | |
NCT06607770: Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers |
|
|
| Recruiting | 1/2 | 20 | RoW | Karelizumab+Apatinib | Zhou Chengzhi | Lung Cancer | 08/26 | 08/27 | | |
NCT06597513: Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC |
|
|
| Not yet recruiting | 1/2 | 10 | NA | auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab, auto-HSCT, Dose-Dense Chemotherapy, Adebrelimab | Zhou Chengzhi | Extensive Stage Small Cell Lung Cancer | 12/25 | 12/26 | | |
NCT05001412: Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC |
|
|
| Recruiting | 1 | 36 | RoW | Camrelizumab; apatinib; carboplatin; etoposide | Zhou Chengzhi, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Extensive Stage Small Cell Lung Cancer | 01/23 | 01/24 | | |
NCT05280873: Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP |
|
|
| Recruiting | 1 | 48 | RoW | Pirfenidone, methylprednisolone, Methylprednisolone | Zhou Chengzhi, Beijing Continent Pharmaceutical Co, Ltd. | Pneumonitis, Malignant Tumor | 10/23 | 10/24 | | |
NCT05826483: Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status |
|
|
| Recruiting | 1 | 20 | RoW | Almonertinib | Guangzhou Institute of Respiratory Disease | Malignant Tumor of Lung, Poor Performance Status | 12/24 | 12/24 | | |
NCT06772454: To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Recruiting | N/A | 60 | RoW | Antitumor therapy, Inhaled preparation for COPD | Guangzhou Institute of Respiratory Disease | Lung Cancer Squamous Cell, COPD | 06/25 | 12/25 | | |
NCT04858828: Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC |
|
|
| Not yet recruiting | N/A | 200 | RoW | | Zhou Chengzhi | Biomarkers | 03/23 | 03/24 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Chengzhi, Zhou |
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 08/25 | 10/25 | | |
NCT05826483: Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status |
|
|
| Recruiting | 1 | 20 | RoW | Almonertinib | Guangzhou Institute of Respiratory Disease | Malignant Tumor of Lung, Poor Performance Status | 12/24 | 12/24 | | |
